Huntingdon Life Sciences and Harlan Laboratories to operate under new brand and name

Huntingdon (UK): Huntingdon Life Sciences (HLS) and Harlan Laboratories have announced that the two companies will be rebranded to reflect the new integrated management structure that has been put in place and the broader product and service offerings of the combined organizations.

Combined company will consist of two business units: Contract Research Services (CRS) and Research Models and Services (RMS)

The new name and rebranding is a significant key milestone that will mark the beginning of a new period for both Harlan and HLS – following a history stretching back more than 80 years.

One of the world's leading branding agencies helped inform the decision, following an extensive review of existing customer relationships, synergies across the two organisations and the projected outlook for the market sectors that they serve. A huge amount of internal integration work, both strategic and operational, has already been completed and the two companies will be formally merged under one brand in the coming months.

Two core business units of Research Model and Services (RMS) and Contract Research Services (CRS) have been established from existing capabilities across Harlan and HLS, as well as subsidiaries of both companies. The RMS business unit provides high-quality research models, lab animal diets and bedding, and support services from 30 sites worldwide. The CRS business unit offers a comprehensive range of drug development and environmental sciences services, including safety assessment, analytical, metabolism, CMC, and regulatory consultancy from nine contract research facilities within Europe, the US and the Middle East.

Throughout this process, both companies have kept customer relationships as the central consideration, and the new company will be able to deliver a far broader range of products and services to their customers from more global locations.

Brian Cass, CEO, commented: "The decision to rebrand the two companies as one entity is the natural progression of a sustained integration process that was put in place last year. It is a symbol of the fact that as one integrated company we are now able to further diversify the range of products and services we can provide to the market, further supporting existing relationships whilst growing our business globally with new customers. It's a hugely exciting time for our company, with our customer-led focus and flexibility in approach, our goal is to establish our new company as the number one development partner for customer service and scientific expertise."

The combined company has 3,500 staff and sales approaching $500 million. As a result of the integration, the company is already the largest provider of research services to the crop protection and chemical industries, the second largest supplier of research models and services, and the third largest in the preclinical pharmaceutical development arena.

The formal rebrand completion date is yet to be finalised, with full execution and implementation later this year.

 


 

For media enquiries, please contact:

Alex Heeley or Tristan Jervis
De Facto Communications
T: +44 207 203 6745 / 6740
E: [email protected] / [email protected]

 

Company contacts:

Katie Bramwell at Huntingdon Life Sciences
Phone: +44 (0) 1480 892748 Email: [email protected]
Andrew Gay at Huntingdon Life Sciences
Phone: + 44 (0) 1480 893073 Email: [email protected]

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.